Loading clinical trials...

A Comparison of Zidovudine (AZT) and Stavudine in HIV-Infected Patients | Clinical Trials | Clareo Health

COMPLETEDNA

A Comparison of Zidovudine (AZT) and Stavudine in HIV-Infected Patients

A Double-Blind Comparison of Zidovudine (AZT) Versus Stavudine (d4T; BMY 27857) for the Treatment of Patients With HIV Infection Who Have Absolute CD4 Lymphocyte Counts Between 50 and 500 Cells/mm3

NCT00002307•Bristol-Myers Squibb

View on ClinicalTrials.gov

Summary

To compare stavudine (d4T) and zidovudine (AZT) in slowing the progression of HIV disease. To compare the antiviral activity of d4T versus AZT as measured by plasma levels of p24 antigen and HIV viremia, and their relative efficacy by improvement and/or absence of adverse changes over time in laboratory parameters associated with HIV infection. To compare the safety of oral doses of d4T to AZT in patients with HIV infection.

Eligibility

Age

13 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Concurrent Medication:
•Allowed:
•AZT.
•Patients must have:
•Documented HIV infection as determined by a positive ELISA and/or Western blot.
•Absolute CD4 count of 100 - 500 cells/mm3 within 90 days prior to registration OR a CD4 count of 50 - 99 cells/mm3 within 30 days prior to registration.
•Prior zidovudine therapy for at least 6 months and currently tolerating at least 500 mg daily.

Exclusion Criteria

•Co-existing Condition:
•Patients with the following symptoms and conditions are excluded:
•Newly diagnosed AIDS-defining opportunistic infection requiring acute therapy at time of enrollment.
•Need for chronic systemic therapy at time of enrollment.
•Intractable diarrhea.
•Signs or symptoms of bilateral peripheral neuropathy at time of screening.
•Demonstrated intolerance to zidovudine therapy.
•Any other clinical conditions that would render the patient unsuitable for study or unable to comply with the dosing requirements.
•Concurrent Medication:
•Excluded:
+12 more criteria

Locations (45)

Univ of Arizona / Health Science Ctr

Tucson, Arizona, United States

East Bay AIDS Ctr

Berkeley, California, United States

Children's Hosp of Los Angeles

Los Angeles, California, United States

Combat Group

Los Angeles, California, United States

Los Angeles County - USC Med Ctr

Los Angeles, California, United States

Cedars Sinai Med Ctr

Los Angeles, California, United States

UCD Med Ctr / AIDS and Related Disorders Clinic

Sacramento, California, United States

Children's Hosp of San Francisco

San Francisco, California, United States

Harbor UCLA Med Ctr

Torrance, California, United States

Univ of Colorado Health Sciences Ctr

Denver, Colorado, United States

Key Dates

Completion Date

December 1, 1994

Last Updated

August 5, 2011

Conditions

HIV Infections

Interventions

Stavudine

DRUG

Zidovudine

DRUG

Skeletal Muscle Energetics and Fatiguability in Older Individuals

NCT04142047

HIVHIV Infections

View study

RECRUITINGPHASE3

A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1

NCT06694805

HIV Infections

View study

RECRUITING

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 5, 2011Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Comparison of Zidovudine (AZT) and Stavudine in HIV-Infected Patients

Inclusion Criteria

Exclusion Criteria

Skeletal Muscle Energetics and Fatiguability in Older Individuals

A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1

Clinic vs Clinic+Community Outreach HPV Self-Collection to Increase Cervical Screening in Women With HIV

Implementation of Screen, Treat, and Triage for Women Living With HIV in La Romana (iSTAR)

Clinical Trial to Evaluate the Safety and Immunogenicity of Hiltonol, Poly-ICLC-adjuvanted CD40.HIVRI.Env (VRIPRO) in Adult Participants Who Previously Participated in HVTN 706

Comprehensive HIV and Harm Prevention Via Telehealth